Fibrotic Disease: from Signaling Pathways and Biomarkers to Molecular Imaging

Area of Science:

• Biomedical imaging
• Molecular biology
• Pathology

Background:

• Fibrotic diseases stem from excessive extracellular matrix (ECM) accumulation after injury, leading to organ dysfunction.
• Key molecular pathways (e.g., TGF-β, PDGF) regulate myofibroblast activation and ECM production in fibrosis.
• Current diagnostics like MRI, CT, and biopsy struggle to differentiate active fibrogenesis from established fibrosis or detect early molecular changes.

Purpose of the Study:

• To review the molecular mechanisms of fibrogenesis.
• To highlight key signaling pathways and biomarkers in fibrotic diseases.
• To discuss current and emerging molecular imaging agents for diagnosing and monitoring fibrosis.

Main Methods:

• Comprehensive literature review of fibrogenesis molecular mechanisms.
• Analysis of signaling pathways and biomarkers involved in fibrosis.
• Evaluation of molecular imaging techniques and agents for fibrotic disease detection.

Main Results:

• Fibrosis progression is driven by complex signaling pathways regulating ECM production and myofibroblast activation.
• Molecular imaging advances, including targeted radiotracers and contrast agents, enable precise detection of fibrotic processes.
• Integration of molecular imaging with targeted probes shows potential for early diagnosis and therapeutic guidance.

Conclusions:

• Molecular imaging represents a significant advancement over traditional methods for fibrotic disease diagnosis.
• Targeted molecular imaging agents can improve the early detection and characterization of fibrosis.
• This approach holds promise for personalized treatment strategies and enhanced clinical management of fibrotic conditions.